Which hedge funds own CRVS? CORVUS PHARMACEUTICALS INC, Q2 2026 13F holders
38 tracked hedge funds disclosed a position in CRVS (CORVUS PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $351.3m in total. The largest holder by portfolio weight is Catalio Capital Management, LP at 3.0% of its book. 11 opened a new position this quarter: Eversept Partners, LP, ACT Capital Management, LLC, Arrowpoint Investment Partners (Singapore) Pte. Ltd., Fox Run Management, L.L.C.. 8 exited: Commodore Capital LP, MPM Bioimpact LLC, Logos Global Management LP.
- 38
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 11
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 8
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $20.8m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $85.8m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $351m
- Combined value Sum of the holders' reported positions in the security.
- 3.1%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Commodore Capital LP | 1.9% | $33.0m |
| MPM Bioimpact LLC | 1.9% | $24.5m |
| Logos Global Management LP | 0.3% | $6.6m |
| Polar Capital Holdings Plc | 0.07% | $15.7m |
| Voloridge Investment Management, LLC | 0.02% | $4.1m |
| Burkehill Global Management, LP | 0.01% | $293k |
| Renaissance Technologies LLC | 0.0% | $1.2m |
| Qube Research & Technologies Ltd | 0.0% | $486k |
Ownership over time
Who discovered CRVS first? Beta
The run: Q1 2025 → Q2 2026, +370%
| MPM Bioimpact LLC | Q4 2025 | – | +2.2 pts |
| Orbimed Advisors LLC | Q1 2017 | 0.5% | +1.4 pts |
| Sphera Funds Management Ltd. | Q2 2016 | 0.2% | +0.4 pts |
| Catalio Capital Management, LP | Q1 2026 | – | +0.1 pts |
| Boxer Capital Management, LLC | Q1 2026 | – | 0.0 pts |
| Diadema Partners LP | Q1 2026 | – | 0.0 pts |
| EcoR1 Capital, LLC | Q2 2017 | – | −0.1 pts |
| Venrock Adviser, LLC | Q3 2021 | – | −1.1 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.